Max Nowicki

Max Nowicki is the Chief Investment Officer at King Tide Capital Management, based in Seattle, WA. In this role, he leads the investment strategy and portfolio management, with a core focus on public biotechnology and life sciences sectors. King Tide Capital Management is recognized for its targeted approach to healthcare, utilizing deep scientific and financial expertise to guide its investments.

Before joining King Tide Capital Management, Max was a Senior Associate at Frazier Healthcare Partners, where he specialized in sourcing and evaluating investments in life sciences, including biotechnology and medical technology companies. His prior experience includes an analytical role at Zymergen, a synthetic biology firm, as well as investment banking work in healthcare M&A at Evercore Partners—these roles strengthened his sectoral acumen and investment judgment in biotech and pharma assets.

Max holds an M.D. from Weill Cornell Medical College and earned a B.A. in physics and biochemistry from Bowdoin College. He is a recipient of the Siegel Family Student Prize at Weill Cornell, underscoring his commitment to rigorous research and excellence. His career is distinguished by a sharp focus on innovative healthcare and biotech investments, and he is noted for founding King Tide Capital Management to execute on these sector-specific strategies.